ニュース

ニュース

Preclinical data on antitumor effects of CA102N in pancreatic cancer were presented at the American Association of Cancer Research (“AACR”) Annual Meeting- April 5-10, 2024, San Diego, California.

19, Apr 2024

Dr. Eskouhie Tchaparian presented data on CA102N, the company’s novel pancreatic cancer drug candidate at the 2024 AACR annual meeting. The poster detailed a series of preclinical studies of CA102N activity in pancreatic cancer models.

Pancreatic cancer is recognized as a highly aggressive and deadly form of cancer. The five-year survival rate for pancreatic cancer is only 13%; therefore, there is an urgent need for new therapeutic drugs to treat pancreatic cancer and improve the overall survival rate of patients.

CA102N primarily inhibits pancreatic cancer cell growth by suppressing the PI3K/Akt/mTOR and Raf/MEK/ERK pathways, inducing apoptosis and inhibiting angiogenesis and cell migration. In in vivo pancreatic cancer models, CA102N demonstrated significant tumor growth inhibition and reduced liver metastasis. Observations of tumor samples from in vivo studies showed that CA102N alters pancreatic cancer stroma by changing its structure and enhances its permeability through the stromal barrier. Compared to current therapeutic drugs, CA102N is expected to overcome treatment limitations imposed by pancreatic tumor stroma.

These results provide scientific evidence of CA102N's efficacy in treating pancreatic cancer. The company plans to file for orphan drug approval by the FDA.

For more information, please refer to the following link: https://aacrjournals.org/cancerres/article/84/6_Supplement/5742/740087/Abstract-5742-Therapeutic-efficacy-of-CA102N-in?searchresult=1

前のページ